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ABSTRACT
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Introduction Cervical cancer (CC) is the second most prevalent female cancer in Malaysia. 
Almost 70% of its’ causal factors are attributable to oncogenic human 
papillomavirus (HPV) types 16, 18 and other risk factors. HPV genotypes 
distributions are also noted to differ by geographical area.
Methods This was cross sectional study conducted in 2007, to determine the 
influencing factors of HPV positivity and prevalence of HPV infections 
among patients with cervical cancer in Universiti Kebangsaan Malaysia 
Medical Centre (UKMMC). Patients’ paraffin-embedded cervical tissues kept 
in the Pathology Department from 1999 to 2007 were randomly selected. A 
total of 81 medical records with complete information were chosen as 
samples and patients were contacted for consent. Tissue samples were further 
derived for PCR DNA for HPV genotyping. Analyses included descriptive 
statistics; bivariate χ2 test and correlation were used to determine relationship 
between factors and HPV positivity. Significance level of less than 0.05 was 
taken as statistically significant.
Results Mean age of cancer diagnosis was at 52 ± 12.2 years. Women of Chinese 
ethnicity was  the highest ethnicity to be HPV positive at 65.4% and 
squamous cell carcinoma was more commonly found (59.3%) compared with 
other types of cancers. The prevalence of HPV positivity was 92.6% with 
type 16 being the most common (74.1%), followed by type 33 (30.9%) and 
18 (22.2%). Multiple HPV infections were a common finding at 54.3%. 
Factors thought to influence positivity i.e. age of intercourse, number of 
sexual partners, number of parity, smoking status of patients and their 
partners, oral contraceptive usage, presence of chronic illnesses and cancer 
stage were not significantly associated with HPV positivity. Increased CC 
severity level was not associated with increased number of HPV infections 
(Pearson correlation 0.58; p =0.607).
Conclusions High HPV positivity at 92.6% was found among ICC patients. Factors 
thought to influence HPV positivity were not significant. The top three HPV 
genotypes were type 16 followed by type 33 and 18. However, local women 
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HPV serotypes findings need to be replicated in a larger population sample.
Keywords HPV - invasive cervical cancer – genotyping - HPV distribution - HPV 
vaccines
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INTRODUCTION
World Health Organisation (WHO) reported that in 
2002 over 471,000 new cases were diagnosed and 
288,000 women died from cervical cancer 
worldwide. The incidence and mortality rate of 
cervical cancer were higher in developing countries 
because of ineffective screenings, lack of 
knowledge of its benefits among women and 
unsustainable screening advocates1. This can be 
very damaging especially in under developed and 
developing countries where the age standardised 
incidence rate can be higher than the world’s 
incidence rate of cervical cancer 2, 3. In Malaysia, 
although various health promotion methods have 
been utilised to promote female cervical screening 
through Pap smear; it remained a daunting task 
where by female population coverage remained 
low at or less than 40%4. Multiple social and 
cultural barriers hamper this progress and the 
cervical cancer incidence and mortality remains 
high causing substantial loss of lives, quality of 
lives and management costs to the country that 
provide health services to these cancer inflicted 
survivors5. 
In Malaysia, the Ministry of Health
(MOH) reported cervical cancer as the second 
leading cause of death after breast cancer among 
women in year 20036 (Malaysia National Cancer 
Registry 2004). The age standardised incidence rate 
in 2003 was 19.7/100,000 population and had 
reduced to 12.2/100,000 in the year 20067. Even 
with the presence of a nationwide health mitigation 
effort through opportunistic cervical cancer 
screening, the screening rate nationwide remained 
low at 43.7% in a 2006 survey4. From the 
Malaysian National Cancer Registry year 2003 and 
2006, cervical cancer incidence rate was highest 
among the Chinese ethnicity, intermediate among 
the Malays and lowest among Indians 6,7. 
Various risk factors 8,9,10 contributed to 
cervical cancer development from general cell 
dysplasia that takes a long time to develop, 
estimation range from few years to a decade. These 
risk factors included ‘adverse’ sexual habits 
(multiple partners, early intercourse), genital 
infection (human papillomavirus or HPV, 
Chlamydia, Herpes), chemical carcinogen (oral 
contraceptive, cigarette smoking) and women 
social status (low socioeconomic status). HPV is 
considered a public health problem, as HPV virus
is sexually transmitted and infects men and women 
alike11, 12. HPV acts as a major risk factor for 
cervical cancer development worldwide 13 but they 
vary by geographical regions and areas some 
commented even by ethnicity14-18. The International 
Agency for Research in Cancer reported that HPV 
types 16 and 18 are carcinogenic and human
specific 3. However more than 100 types of HPV 
have been discovered; of which approximately 15 
are oncogenic while newer types are currently 
being identified12, 13. Approximately 30 types of 
HPV are associated with anogenital tract 
infections13. 
The presence of both bivalent and 
quadrivalent human papillomavirus (HPV)
vaccines in Malaysia’s private health market have 
raised concerns on vaccines safety, applicability 
and suitability of mass vaccinations, the 
development of various cross protections by 
different vaccines efficacy by different vaccine 
types19. There are also issues on whether there will 
be a possibility of other genotypes of HPVs’ taking 
over from types 16 and 18 since vaccine will 
eradicate these genotypes from Malaysia’s women 
population20. Since both novel vaccines have only 
been tested since 7 years ago, the possibility of a 
booster is present even though it will be unlikely.
A study in Thailand demonstrated the
HPV type 16 was most commonly found in 
squamous cell carcinoma (SCC), followed by HPV 
types 18, 58, 52, 31, 33 and 3917. In another study, 
about 80% of HPV types 16, 18, 45, 31 and 33 
were distributed in SCC 21. Among the non-SCC 
(this include cervical intraepithelial neoplasia 
(CIN) 3, adenosquamous or adenocarcinoma cell), 
HPV types 16 was the most common type followed 
by types 18 and 33. In other studies, it had been 
showed that HPV types 18 were found in 
adenosquamous cell at a prevalence rate of ranging 
between 42.9% 10 to 54.3% 17. The distribution of 
HPV types in other geographical area showed the 
same result that demonstrated that HPV types 16 
(44%) and 18 (39%) were the most dominant in 
Jakarta Indonesia22, 23. In Washington, HPV type 16 
dominated followed by type 18 and this followed 
the general world trend 14, 16, 22. This study was 
carried out to determine the factors associated with 
invasive cervical cancer based on cervical tissues. 
Funding was provided by Merck Sharp and Dohme 
Malaysia through the National Public Health 
Physicians Association.
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METHODS
This was a cross sectional study in 2006, taking 
retrospective data of women from the year 1999 to 
2007. Eligible women were women whose ICC
paraffin-embedded cervical tissues kept in 
Universiti Kebangsaan Malaysia Medical Centre 
(UKMMC) Pathology Department. Invasive CC 
was defined as high-grade squamous intraepithelial 
lesion (HSIL) or CIN3 and above (Stage 1A-4B). 
Patients excluded were women below the age of 30
or above 80 years of age, who have expired from 
whatever cause of mortality, patients who were not 
contactable or women with other concurrent types 
of cancer. 
Two methods of data gatherings were 
performed. The first was data gathered using data 
extraction forms that collected patients’ sexual 
behaviour, reproductive history (number of 
children), past usage of oral contraceptives, 
occupations and Pap smear screening history. The 
second method, subjects were contacted through
telephone and direct interviews were carried out to 
gather more information especially when there was 
insufficient information from the responders’ 
medical records. Patients or caretakers consents to 
participate in the research were obtained prior the 
telephone interviews as well as the ethical approval 
from UKMMC research ethical committee.
Cervical cancer tissue samples were analysed using 
real time Polymerase Chain Reaction (PCR) to 
determine HPV positivity (defined as presence of at 
least one type of HPV genotype). 
RESULTS
Socio demographic Profiles
Out of 125 patients, 81 patients (64.8% response 
rate) have complete information required for the 
study. The block specimens of those 81 patients 
were subjected to PCR study to identify the HPV 
types. Table 1 described the socio-demographic 
characteristic of the ICC patients. From reviews of 
patients’ history from their health record notes, 
majority of our respondents developed cervical 
cancer at the age of between 30 to 39 years. 
However, the mean age of respondents during 
admission in this study was carried out was at 52.0 
± 12.2 years. About 65.4% of the subjects in this 
study were of Chinese ethnicity, followed by
Malays at 25.9%, Indians at 4.9% and most of them 
were currently married women at 65.4%.
Risk Factors for HPV Related CC
Table 2 elucidated that 95.5% of patients with early 
sexual intercourse (defined as sexual intercourse 
below the age of 18 years) had HPV related 
cervical cancer compared to 93.0% among those 
with late sexual intercourse debut. This relationship 
was not significant.
Of the 66 patients with one sexual partner, 
93.9% was infected with HPV and the result was 
also higher for the patients with more the one 
sexual partner (85.7%). In term of parity, 90.0% of 
patients with three children and below developed 
HPV related cervical cancer. This percentage 
increased at 95.1% in patients with more than three 
children. However, this relationship was not 
significant (p=0.65).
Most of the responders (n=73; 90.1%) 
stated that they never smoked and all the eight 
smokers in the study were HPV positive compared 
to 91.8% among non-smokers. All patients who 
ever used contraceptive method (n=21; 100%) was 
HPV positive compared to 90.0% of those not on 
contraceptive methods. Spouse smoking status was 
associated with higher HPV positive status at 
92.9% compared with 91.4% of spouse who are 
non smokers. The presences of chronic illnesses 
(DM, Hypertension, Hepatitis B, Anaemia, Stroke, 
and Ischemic Heart Disease) were not associated 
with HPV positivity. There was no significant 
relationship between HPV positivity with cancer 
stage (χ2=0.886; p=0.927). Increased stage of ICC 
was not significantly associated with increased 
number of HPV infections (Pearson correlation of 
0.058; p=0.607).
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Table 1 Socio-Demographic Characteristics of Patients with ICC.
Characteristics N %
Age (years) (n=81) Mean 52.0 ± 12.2
       30 – 39 13 16.0
       40 – 49 19 23.5
       50 – 59 26 32.1
      ≥ 60 23 28.4
Income (RM)                                                                     Median RM 725 (IQR 1000-1575)
Ethnic (n=81)
      Malay 21 25.9
      Chinese 53 65.4
      Indian 4 4.9
      Others 3 3.7
Marital Status (n=81)
     Single 2 2.5
     Married 53 65.4
     Divorcee 11 13.6
     Widowed 15 18.5
Education level (n=78)
     Never school 25 32.1
     Primary school 29 37.2
     Secondary school 20 25.6
    Tertiary/University 4 5.1
Patients’ occupation (n=81)
     Professional 4 4.8
     Business 2 2.5
     Agriculture 2 2.5
     Factory 2 2.5
     Housewife 51 62.9
     Others 20 24.9
Smoker (current) (n=81)
     Yes 8 9.9
     No 73 90.1
No of sexual partners (n=80)
     Single 66 82.5
     Multiple 
Usage of oral contraceptives(n=81)
     Yes
     No 
Pap smear screening done (n=80) 
     Yes
     No
14
21
60
44
36
17.5
25.9
74.1
55
45
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Table 2 Factors associated with HPV Positivity Status.
Factor HPV Positivity Status n, (%) χ2 p
Positive Negative
Early sexual intercourse (n=79)
             Yes 21 (95.5) 1 (4.5) 0.00 1.00
             No 53 (93.0) 4 (7.0)
No. of sexual partner (n=80)
             1 62 (93.9) 4 (6.1) 0.25 0.62
            ≥ 2 12 (85.7) 2 (14.3)
Parity (number of children) 
(n=81)
           0-3 36 (90.0) 4 (10.0) 0.21 0.65
           ≥4 39 (95.1) 2 (4.9)
Ever use contraceptive method 
(n=81)
          Yes 21 (100.0) 0 (0.0) 1.04 0.37
          No 54 (90.0) 6 (10.0)
Smoking (n=81)
          Yes 8 (100.0) 0 (0.0) 0.17 0.9
          No 67 (91.8) 6 (8.2)
*Spouse’s smoking (n=77)
           Yes 39 (92.9) 3 (7.1) 0.01 1.00
           No 32 (91.4) 3 (8.6)
Chronic illness (n=81)
          Yes 37 (92.5) 3 (7.5) 0.01 1.00
          No 38 (92.7) 3 (7.3)
Cancer Stage (n=81)
          CIN3/HSIL 18 (90.0) 2 (10.0) 0.886 0.927
          Stage 1 22 (91.7) 2 (8.3)
          Stage 2 20 (95.2) 1 (4.8)
          Stage 3 10 (90.9) 1 (9.1)
          Stage 4 5 (100.0) 0 (0.0)
* Yates correction
Tissue Sample Histology and HPV Type
The most common histology types found in this 
study was squamous cell carcinomas (SCC) at 
73.8%, followed by CIN3 at 23.5%, 
adenocarcinoma at 18.5% and adenosquamous 
carcinoma at 1.2%. However, co-infections with 
types 16/33 were present in SCC at 73.3% and 20% 
in adenocarcinoma. HPV coinfections with types 
16/18 was found to be dominant in SCC at 58.3%, 
followed by 41.7% in adenocarcinoma. Co-
infection with types 18/33 was dominant again in 
SCC at 66.7%, followed by in adenocarcinoma at 
33.3%. The full result of this study was published 
elsewhere24.
International Journal of Public Health Research Vol 1 No 1 2011, pp (13-22)
19
Table 3 Distribution (%) of HPV Positivity and Genotypes.
HPV 
Positivity 
and Types
Percentage (%)
n=75* n=81**
SCC 
(73.8%)
Adeno-
squamous 
(1.2%)
Adeno-
carcinoma
(18.5%)
CIN3/
HSIL 
(24.0%)
Stage 1 
(28.0%)
Stage 2 
(28.0%)
Stage 3 
(13.3%)
Stage 4 
(6.7%)
Positivity 75.4 1.8 22.8 24.0 29.3 26.7 13.3 6.7
16 (n=60) 75.0 2.1 22.9 20.0 31.7 30.0 11.7 6.7
18 (n=18) 53.3 0 46.7 16.7 33.3 22.2 22.2 5.6
33 (n=25) 77.8 5.6 16.7 28.0 20.0 44.0 4.0 4.0
16/33 (n=20) 73.3 6.7 20.0 25.0 15.0 50.0 5.0 5.0
16/18 (n=15) 58.3 0 41.7 20.0 33.3 20.0 20.0 6.7
18/33 (n=6) 66.7 0 33.3 50.0 0 33.3 0 16.7
*n=75 are among the ICC only
**n=81 are among pre invasive and ICC
DISCUSSION
The higher prevalence of Chinese ethnicity among 
patients diagnosed to have cervical cancer in this 
study was consistent with the Malaysian Cancer 
Registry 6,7 (year 2003-2006) that reported that the 
incidence was highest among the Chinese at age 
standardised rate of 33.6 per 100 000 and Malays 
are the lowest ethnic to developed cancer. However 
this study showed that the Malays were the second 
group while Indians had the lowest prevalence of 
cancer. It might be due to sampling bias because 
UKMMC being a teaching hospital and of public 
entity was being visited by more Malays than 
Indian patients. 
Women as young as 30 years developed 
ICC in this study. The development of cervical 
cancer was common in women older than 35 years 
age 6,7. In the Africa region, the mean age of the 
patients with cervical cancer was 33.9±11.4 years
and in southern European region was at 56.5 ±14.3 
year16. Younger age of sexual debut triggered
higher risk of acquiring HPV infection through 
immaturity of cervical cells and the inability to 
counter persistent infection3, 11, 24. In the Durex 
sexual survey done in Malaysia, the age of sexual 
debut for women in this country was as young as 
17 years old25. This is the results of globalisation 
and religious /cultural disintegration occurs, where 
by the age of sexual debut will reduce although the 
age of actual marriage and commitment may 
increase11, 15, and 18. This sexual novelty of young 
woman and their male partner/partners puts her at 
risk of acquiring HPV infection through sexual 
intercourses. In subsequent sexual activities, these 
HPV infected women may transmit the infection to 
other partners later on and possibility to their
newborns; presenting with recurrent laryngeal
respiratory papillomatosis that needs repeated and 
intensive procedures to remove the tumour26. The 
unknown local HPV prevalence among women and 
among men remain as risk factors, unfortunately
that information are not readily available as the 
importance and cost effectiveness are still debated
14,16,18,26. The sexual activity of men having sex 
with men in Malaysia may not be as rampant as in 
other countries but this adds fuel to the fire where 
the quadrivalent vaccine is highly sought after by 
these ‘high risk’ groups as it covers against genital 
warts 15,20,26. From previous studies, it has been
shown that total HPV positivity among cervical 
cancer and pre invasive diseases were at 76% 27, 28 
.The most dominant types from these studies were
types 18 at 68% and type 16 at 58%. 
Consistent with other studies 2,9,10, (if 
HSIL had been omitted) then SCC (73.8%) was 
most commonly found among our respondents, 
compared to adenocarcinoma (18.5%) and 
adenosquamous carcinoma (1.2%). Independent 
single infection from our result, demonstrated that
HPV type 16 (75.0%) and type 33 (77.8%) 
dominated in SCC. Both HPV 16 and 33 were from
A9 species, rather than type 18 which is from the 
A7 species. HPV type 18 was found to be more 
dominant in adenocarcinoma at 46.7%. UKMMC 
being a teaching hospital and as a tertiary referral 
centre, would reflect the geno-positivity of 
Malaysian women inflicted with cervical cancers. 
However this study was a single centre study, thus 
a wider multi centre study among general women 
population would be helpful albeit costly as HPV 
positivity yield might not be very high among ‘low 
risk’ women. These current findings stipulated that 
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genotypes 16 and 18 played a significant role in 
local cervical cancer development as well. The
high prevalence of HPV type 33 remained a 
deviation against the normal HPV trend except in 
certain studies from Hong Kong 29, Japan14, 
Uganda15 and Iran30. These papers suggested that
following cervical infection with HPV type 16, 
other types may predominate rather than the usual 
HPV type 18.
However from this study, the results 
indicated no significant relationships between HPV 
positivity status and factors (age of first 
intercourse, number of sexual partners and number 
of children, contraceptive usage, patients’ and 
spouses’ smoking status, presence of chronic 
illness and CC stage). Other factors could have 
played significant factors in this study. This might 
be incongruent with other literatures that suggested 
the mentioned factors to predict or associated with 
the development of HPV related disease and 
positive status. This could be due to the limited 
sample size among ICC patients taken as 
responders in this study. Next, enter the question of 
the effects of mass vaccination. If mass vaccination 
program are to be implemented, will its properties 
of cross protection causes serotypes replacement of 
the HPV epidemiology of the population and 
change the immunity of local women population? 
These answers are a long way to be discovered and 
till then, these possibilities have to further explored 
and documented.
CONCLUSIONS
HPV infection and positivity was high among 
women inflicted with ICC in Malaysia. The 
epidemiology in local setting is extremely 
important as it may change local HPV 
epidemiology once mass vaccination is initiated on 
a mass population scale. There raise another 
question of will there be a need for second line of 
HPV vaccines or will the cross protections 
presumably in HPV vaccines against HPVs in their 
phylogenetic tree be sufficient to render protection 
against cancer development.
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